1177 related articles for article (PubMed ID: 7565624)
1. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
Felder CC; Joyce KE; Briley EM; Mansouri J; Mackie K; Blond O; Lai Y; Ma AL; Mitchell RL
Mol Pharmacol; 1995 Sep; 48(3):443-50. PubMed ID: 7565624
[TBL] [Abstract][Full Text] [Related]
2. Mead ethanolamide, a novel eicosanoid, is an agonist for the central (CB1) and peripheral (CB2) cannabinoid receptors.
Priller J; Briley EM; Mansouri J; Devane WA; Mackie K; Felder CC
Mol Pharmacol; 1995 Aug; 48(2):288-92. PubMed ID: 7651362
[TBL] [Abstract][Full Text] [Related]
3. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase.
Slipetz DM; O'Neill GP; Favreau L; Dufresne C; Gallant M; Gareau Y; Guay D; Labelle M; Metters KM
Mol Pharmacol; 1995 Aug; 48(2):352-61. PubMed ID: 7651369
[TBL] [Abstract][Full Text] [Related]
4. The endocannabinoid noladin ether acts as a full agonist at human CB2 cannabinoid receptors.
Shoemaker JL; Joseph BK; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Aug; 314(2):868-75. PubMed ID: 15901805
[TBL] [Abstract][Full Text] [Related]
5. The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines.
Derocq JM; Bouaboula M; Marchand J; Rinaldi-Carmona M; Ségui M; Casellas P
FEBS Lett; 1998 Apr; 425(3):419-25. PubMed ID: 9563506
[TBL] [Abstract][Full Text] [Related]
6. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction.
Felder CC; Briley EM; Axelrod J; Simpson JT; Mackie K; Devane WA
Proc Natl Acad Sci U S A; 1993 Aug; 90(16):7656-60. PubMed ID: 8395053
[TBL] [Abstract][Full Text] [Related]
7. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation.
Felder CC; Joyce KE; Briley EM; Glass M; Mackie KP; Fahey KJ; Cullinan GJ; Hunden DC; Johnson DW; Chaney MO; Koppel GA; Brownstein M
J Pharmacol Exp Ther; 1998 Jan; 284(1):291-7. PubMed ID: 9435190
[TBL] [Abstract][Full Text] [Related]
8. Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide.
Gonsiorek W; Lunn C; Fan X; Narula S; Lundell D; Hipkin RW
Mol Pharmacol; 2000 May; 57(5):1045-50. PubMed ID: 10779390
[TBL] [Abstract][Full Text] [Related]
9. The peripheral cannabinoid receptor: adenylate cyclase inhibition and G protein coupling.
Bayewitch M; Avidor-Reiss T; Levy R; Barg J; Mechoulam R; Vogel Z
FEBS Lett; 1995 Nov; 375(1-2):143-7. PubMed ID: 7498464
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
Showalter VM; Compton DR; Martin BR; Abood ME
J Pharmacol Exp Ther; 1996 Sep; 278(3):989-99. PubMed ID: 8819477
[TBL] [Abstract][Full Text] [Related]
11. Characterization of two cloned human CB1 cannabinoid receptor isoforms.
Rinaldi-Carmona M; Calandra B; Shire D; Bouaboula M; Oustric D; Barth F; Casellas P; Ferrara P; Le Fur G
J Pharmacol Exp Ther; 1996 Aug; 278(2):871-8. PubMed ID: 8768742
[TBL] [Abstract][Full Text] [Related]
12. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
Lin S; Khanolkar AD; Fan P; Goutopoulos A; Qin C; Papahadjis D; Makriyannis A
J Med Chem; 1998 Dec; 41(27):5353-61. PubMed ID: 9876105
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.
Schatz AR; Lee M; Condie RB; Pulaski JT; Kaminski NE
Toxicol Appl Pharmacol; 1997 Feb; 142(2):278-87. PubMed ID: 9070350
[TBL] [Abstract][Full Text] [Related]
14. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
15. Agonist-directed trafficking of response by endocannabinoids acting at CB2 receptors.
Shoemaker JL; Ruckle MB; Mayeux PR; Prather PL
J Pharmacol Exp Ther; 2005 Nov; 315(2):828-38. PubMed ID: 16081674
[TBL] [Abstract][Full Text] [Related]
16. Activation of brain-type cannabinoid receptors interferes with preimplantation mouse embryo development.
Yang ZM; Paria BC; Dey SK
Biol Reprod; 1996 Oct; 55(4):756-61. PubMed ID: 8879486
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1).
Hillard CJ; Manna S; Greenberg MJ; DiCamelli R; Ross RA; Stevenson LA; Murphy V; Pertwee RG; Campbell WB
J Pharmacol Exp Ther; 1999 Jun; 289(3):1427-33. PubMed ID: 10336536
[TBL] [Abstract][Full Text] [Related]
18. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
19. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
Bouaboula M; Poinot-Chazel C; Bourrié B; Canat X; Calandra B; Rinaldi-Carmona M; Le Fur G; Casellas P
Biochem J; 1995 Dec; 312 ( Pt 2)(Pt 2):637-41. PubMed ID: 8526880
[TBL] [Abstract][Full Text] [Related]
20. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor.
Glass M; Felder CC
J Neurosci; 1997 Jul; 17(14):5327-33. PubMed ID: 9204917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]